BioCentury on BioBusiness,
Sanofi, Third Rock form Warp Drive Bio to pursue genomic discovery
Related tables, figures and sidebars
Warping the VC model
Monday, January 16, 2012
While the buzz at last week's
30th Annual JPMorgan Healthcare Conference centered on the $2.5 billion takeout
of Inhibitex Inc. (NASDAQ:INHX) by Bristol-Myers Squibb (NYSE:BMS),
Sanofi CEO Christopher Viehbacher was working to focus investors on an early
stage investment in Warp Drive Bio LLC.
Warp Drive is using genomics to
identify natural drug products in the sequence of microbes, including products
that target pathways previously considered "undruggable." The biotech
was launched by Third Rock Ventures and Sanofi with up to $125
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]